Washed Microbiota Transplantation for the Treatment of Oncotherapy-Related Intestinal Complications

Launched by THE SECOND HOSPITAL OF NANJING MEDICAL UNIVERSITY · Jan 20, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called Washed Microbiota Transplantation (WMT) to help patients who are experiencing intestinal problems related to cancer therapies, like chemotherapy or radiation. Our gut contains a diverse community of bacteria, known as microbiota, which can influence our health, including how cancer develops and progresses. The trial aims to see if WMT can improve these intestinal issues and enhance the quality of life for patients undergoing cancer treatment.

To participate in this study, patients need to be at least 18 years old and have a diagnosed malignant tumor. They should be experiencing gastrointestinal symptoms such as abdominal pain, diarrhea, or difficulty with bowel movements after their cancer treatment. Participants must also be in stable health with a life expectancy of at least three months. During the trial, participants can expect to receive the WMT treatment and be closely monitored for its effects. It’s important to note that certain individuals, such as pregnant women or those with specific medical conditions, may not be eligible to join.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥18 years old; 2. Diagnosed as malignant tumor; 3. Patients who underwent cancer-related treatment suffering from gastrointestinal symptoms(e.g., abdominal pain, diarrhea, abdominal distension, and difficulty defecating) occurred after standard tumor therapy (such as chemotherapy, radiation, immunotherapy, surgical treatment, etc.); 4. Estimated time of survival ≥ 3 months, and vital signs were stable); 5. Physically qualified and intended to undergo FMT;
• Exclusion Criteria:
• • 1. Patients who were pregnant or nursing; 2. Patients who were unable or unwilling to undergo a gastroscopy or colonoscopy; 3. Patients with cardiopulmonary failure; 4. Antibiotics, PPI, probiotics, and other drugs that alter gut microbiota were used in the previous week; 5. history of inflammatory bowel disease and intestinal symptoms unrelated to tumor treatment; 6.Serious uncontrolled diseases and acute infectious diseases；